Clinical, Molecular, and Bioinformatic Study of Common Thrombophilia Mutation Factor V Leiden
Advances in Experimental Medicine and Biology · 2026
DOI: 10.1007/978-3-032-03398-7_10 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Experimental Medicine and Biology, 2026. Verfasst von Antonia Angelopoulou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Orofacial Genetics, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Factor V, Thrombophilia, Computational Biology, Mutation. Die Arbeit nennt 65 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The most common genetic cause associated with thrombophilia is Leiden mutation (G1691A) of the coagulation factor V (F5) gene. MATERIALS AND METHODS: Data collected anonymously from 355 unrelated Greeks examined for the above mutation were analyzed. Bioinformatic investigation was conducted for factor V, including phylogenetic analysis, genetic network analysis, and 3D modeling of wild-type and Leiden protein. RESULTS: Analysis confirmed the importance of F5 Leiden in thrombosis and the significance of a positive family history of thrombosis. In silico analysis of the F5 Leiden revealed a linkage between mammalian species and a potential functional interaction of F5 with 25 other genes, several of which have been associated with cardiovascular diseases. 3D modeling revealed that the Leiden mutation confers an H-bond network alteration in the functional region of FV, resulting in a hypercoagulable state. CONCLUSIONS: This study highlighted the great value of a positive family history of thrombosis and the importance of testing for this common mutation as prevention strategy components for thrombophilia, including thrombotic brain aneurysms. Bioinformatic analysis indicated the importance of the Leiden mutation in protein structure and function. The findings of this study increase understanding of molecular and clinical features of thrombophilia and may eventually lead to better prevention of thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Orofacial Genetics, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Molecular Genetics, Cephalogenetics Center, Athens, Greece.
- Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.
- Laboratory of Molecular Endocrinology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
- Faculty of Natural and Mathematical Sciences, King's College London, London, UK.
- University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair of Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Zitieren
APA
Angelopoulou, A., Papakonstantinou, E., Vlachakis, D., Chrousos, G. P., Cosmidis, N., & Yapijakis, C. (2026). Clinical, Molecular, and Bioinformatic Study of Common Thrombophilia Mutation Factor V Leiden. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-3-032-03398-7_10
Vancouver
Angelopoulou A, Papakonstantinou E, Vlachakis D, Chrousos GP, Cosmidis N, Yapijakis C. Clinical, Molecular, and Bioinformatic Study of Common Thrombophilia Mutation Factor V Leiden. Advances in Experimental Medicine and Biology. 2026. doi:10.1007/978-3-032-03398-7_10
BibTeX
@article{Angelopoulou2026,
author = {Angelopoulou, Antonia and Papakonstantinou, Eleni and Vlachakis, Dimitrios and Chrousos, George P and Cosmidis, Nikolaos and Yapijakis, Christos},
title = {Clinical, Molecular, and Bioinformatic Study of Common Thrombophilia Mutation Factor V Leiden},
journal = {Advances in Experimental Medicine and Biology},
year = {2026},
doi = {10.1007/978-3-032-03398-7_10}
}
EUVIMED